Salarius Pharmaceuticals

<!-- Name:DistributionId Value:8789036 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:8737683 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration and begin a Phase 1 trial in 2023…

Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes 16 issued patents across six unique patent families…

Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting later this year…

HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of new treatment options, today announced…

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible…

HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, hematologic cancers and…

HOUSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, today announced an…

HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic…